

S 4327

A bill to require regulatory review of pharmaceutical products from Chinese entities, and for other purposes.

Congress: 119 (2025–2027, Current)

Chamber: Senate

Introduced: Apr 16, 2026

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Apr 16, 2026)

Official Text: <https://www.congress.gov/bill/119th-congress/senate-bill/4327>

Sponsor

Name: Sen. Cotton, Tom [R-AR]

Party: Republican • **State:** AR • **Chamber:** Senate

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Apr 16, 2026

Subjects & Policy Tags

No subjects or policy tags are listed for this bill.

Related Bills

No related bills are listed.

Summary

No summary is currently available for this bill.

Actions Timeline

- **Apr 16, 2026:** Introduced in Senate
- **Apr 16, 2026:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- **Apr 16, 2026:** Introduced in Senate
- **Apr 16, 2026:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- **Apr 16, 2026:** Introduced in Senate
- **Apr 16, 2026:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.